➤ 2021 ASCRS Annual Meeting update ➤ FDA approves new monofocal IOL ➤ First patient dosed in Phase 2 trial for investigational DED therapy ➤ Phase 2a trial initiated for add-on wet AMD therapy
➤ Enrollment complete for Phase 3 studies of investigational dry eye drug ➤ Update from two Glaukos trials ➤ Study: Remote monitoring with implantable IOP sensor affects clinical decision making ➤ ASCRS events
It’s important to address underlying conditions prior to cataract surgery, and dry eye is one such condition. Physicians must identify and treat it to ensure the tear film is optimized and measurements are correct.
With the COVID-19 pandemic temporarily closing practices around the country, many ophthalmologists had to figure out how to still communicate with and treat their patients. Several physicians commented on how the pandemic has affected their dry eye patient population and trends they have seen.
A retrospective study based on insurance claims data is giving real-world insights into prescribing/treatment patterns for two dry eye medications—cyclosporine ophthalmic emulsion (Restasis, Allergan) and lifitegrast ophthalmic solution (Xiidra, Novartis).1 In doing so, researchers can make inferences on adherence, discontinuation, and more.
When teens come into the clinic, it’s important to consider that they might have dry eye or meibomian gland disease. Investigators in a recent study found that among minors coming in for eye exams, 15% were experiencing dry eye discomfort and 9% had signs of meibomian gland dropout, according to lead investigator Anna Tichenor, PhD.1
any practitioners are now reaching for Xiidra (lifitegrast, Shire, Lexington, Massachusetts) 5% for dry eye cases, but sometimes a patient may not initially be considered a success. Here’s what leading practitioners are doing to help more patients find respite with Xiidra.
Dry eye is the single most common reason that patients come into a practitioner’s office, with a prevalence of around 40% of those seeking ophthalmic care, according to Hank Perry, MD, Ophthalmic Consultants of Long Island, New York. What may not be clear in an office visit is that the patient’s sleep position may be a prime factor in his or her condition.
Meibomian gland dysfunction (MGD) is a common finding among patients who seek eyecare. In many patients, the disease is completely asymptomatic. In others, the severity can range from being a mild annoyance to significantly impacting vision and quality of life.
Supplements aimed at treating dry eye have garnered increasing attention from ophthalmologists, but spotty data has limited their use.